183 related articles for article (PubMed ID: 17664589)
1. Dosimetric impact of tantalum markers used in the treatment of uveal melanoma with proton beam therapy.
Newhauser WD; Koch NC; Fontenot JD; Rosenthal SJ; S Gombos D; Fitzek MM; Mohan R
Phys Med Biol; 2007 Jul; 52(13):3979-90. PubMed ID: 17664589
[TBL] [Abstract][Full Text] [Related]
2. Monte Carlo simulations of the dosimetric impact of radiopaque fiducial markers for proton radiotherapy of the prostate.
Newhauser W; Fontenot J; Koch N; Dong L; Lee A; Zheng Y; Waters L; Mohan R
Phys Med Biol; 2007 Jun; 52(11):2937-52. PubMed ID: 17505081
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo simulations of a nozzle for the treatment of ocular tumours with high-energy proton beams.
Newhauser W; Koch N; Hummel S; Ziegler M; Titt U
Phys Med Biol; 2005 Nov; 50(22):5229-49. PubMed ID: 16264250
[TBL] [Abstract][Full Text] [Related]
4. Monte Carlo investigation of collimator scatter of proton-therapy beams produced using the passive scattering method.
Titt U; Zheng Y; Vassiliev ON; Newhauser WD
Phys Med Biol; 2008 Jan; 53(2):487-504. PubMed ID: 18185001
[TBL] [Abstract][Full Text] [Related]
5. Intraoperative localization of tantalum markers for proton beam radiation of choroidal melanoma by an opto-electronic navigation system: a novel technique.
Amstutz CA; Bechrakis NE; Foerster MH; Heufelder J; Kowal JH
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1361-6. PubMed ID: 21665382
[TBL] [Abstract][Full Text] [Related]
6. A beam source model for scanned proton beams.
Kimstrand P; Traneus E; Ahnesjö A; Grusell E; Glimelius B; Tilly N
Phys Med Biol; 2007 Jun; 52(11):3151-68. PubMed ID: 17505095
[TBL] [Abstract][Full Text] [Related]
7. Clinical implementation of full Monte Carlo dose calculation in proton beam therapy.
Paganetti H; Jiang H; Parodi K; Slopsema R; Engelsman M
Phys Med Biol; 2008 Sep; 53(17):4825-53. PubMed ID: 18701772
[TBL] [Abstract][Full Text] [Related]
8. Dosimetric advantages of IMPT over IMRT for laser-accelerated proton beams.
Luo W; Li J; Fourkal E; Fan J; Xu X; Chen Z; Jin L; Price R; Ma CM
Phys Med Biol; 2008 Dec; 53(24):7151-66. PubMed ID: 19033641
[TBL] [Abstract][Full Text] [Related]
9. Dosimetric validation of the MCNPX Monte Carlo simulation for radiobiologic studies of megavoltage grid radiotherapy.
Zhang H; Johnson EL; Zwicker RD
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1576-83. PubMed ID: 17126214
[TBL] [Abstract][Full Text] [Related]
10. Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO).
Dendale R; Lumbroso-Le Rouic L; Noel G; Feuvret L; Levy C; Delacroix S; Meyer A; Nauraye C; Mazal A; Mammar H; Garcia P; D'Hermies F; Frau E; Plancher C; Asselain B; Schlienger P; Mazeron JJ; Desjardins L
Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):780-7. PubMed ID: 16647221
[TBL] [Abstract][Full Text] [Related]
11. Quantification of dose perturbations induced by external and internal accessories in ocular proton therapy and evaluation of their dosimetric impact.
Carnicer A; Angellier G; Thariat J; Sauerwein W; Caujolle JP; Hérault J
Med Phys; 2013 Jun; 40(6):061708. PubMed ID: 23718587
[TBL] [Abstract][Full Text] [Related]
12. A point dose method for in vivo range verification in proton therapy.
Lu HM
Phys Med Biol; 2008 Dec; 53(23):N415-22. PubMed ID: 18997263
[TBL] [Abstract][Full Text] [Related]
13. Experimental measurements and Monte Carlo simulations for dosimetric evaluations of intrafraction motion for gated and ungated intensity modulated arc therapy deliveries.
Oliver M; Gladwish A; Staruch R; Craig J; Gaede S; Chen J; Wong E
Phys Med Biol; 2008 Nov; 53(22):6419-36. PubMed ID: 18941277
[TBL] [Abstract][Full Text] [Related]
14. Proton therapy of uveal melanomas: intercomparison of MRI-based and conventional treatment planning.
Marnitz S; Cordini D; Bendl R; Lemke AJ; Heufelder J; Simiantonakis I; Kluge H; Bechrakis NE; Foerster MH; Hinkelbein W
Strahlenther Onkol; 2006 Jul; 182(7):395-9. PubMed ID: 16826358
[TBL] [Abstract][Full Text] [Related]
15. Dose perturbations and image artifacts caused by carbon-coated ceramic and stainless steel fiducials used in proton therapy for prostate cancer.
Cheung J; Kudchadker RJ; Zhu XR; Lee AK; Newhauser WD
Phys Med Biol; 2010 Dec; 55(23):7135-47. PubMed ID: 21076190
[TBL] [Abstract][Full Text] [Related]
16. Peripheral dose in ocular treatments with CyberKnife and Gamma Knife radiosurgery compared to proton radiotherapy.
Zytkovicz A; Daftari I; Phillips TL; Chuang CF; Verhey L; Petti PL
Phys Med Biol; 2007 Oct; 52(19):5957-71. PubMed ID: 17881812
[TBL] [Abstract][Full Text] [Related]
17. Dosimetric impact of fiducial markers in patients undergoing photon beam radiation therapy.
Vassiliev ON; Kudchadker RJ; Kuban DA; Frank SJ; Choi S; Nguyen Q; Lee AK
Phys Med; 2012 Jul; 28(3):240-4. PubMed ID: 21875820
[TBL] [Abstract][Full Text] [Related]
18. [Preliminary dosimetry study of the Orsay synchrocyclotron proton beam with a view to applying it therapeutically].
Rosenwald JC; Bridier A; Sabattier R; Guillot R; Louis M; Schlienger P; Habrand JL; Desjardins L; Haye C; Bloch-Michel E
Ophtalmologie; 1990; 4(1):123-7. PubMed ID: 2174529
[TBL] [Abstract][Full Text] [Related]
19. Shielding design for a laser-accelerated proton therapy system.
Fan J; Luo W; Fourkal E; Lin T; Li J; Veltchev I; Ma CM
Phys Med Biol; 2007 Jul; 52(13):3913-30. PubMed ID: 17664585
[TBL] [Abstract][Full Text] [Related]
20. Monte Carlo simulation of a protontherapy platform devoted to ocular melanoma.
Hérault J; Iborra N; Serrano B; Chauvel P
Med Phys; 2005 Apr; 32(4):910-9. PubMed ID: 15895573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
